论文部分内容阅读
骨髓间充质干细胞(BM-MSC)除了具有自我复制、多向分化潜能、低免疫原性外,还具有可归巢至损伤局部,向心肌细胞及脉管系统分化,通过旁分泌作用分泌多种因子及动员内在的心肌干细胞等生物学特性,因此成为缺血性疾病治疗中细胞及基因治疗的理想工程细胞。但是BM-MSC应用于缺血性心脏病(IHD)治疗仍有诸多问题亟待解决,相信随着研究的深入,人类必将利用间充质干细胞治疗这种新的策略攻克IHD治疗中的一系列难题。
Bone marrow mesenchymal stem cells (BM-MSCs) not only have the potential of self-replication, multi-directional differentiation and low immunogenicity, but also have homing to local injury, cardiomyocyte and vasculature differentiation and secretion by paracrine Biological factors such as mobilization of intrinsic cardiac stem cells and other biological characteristics, and therefore become an ideal engineering cell for the treatment of ischemic diseases and gene therapy. However, there are still many problems to be solved in the treatment of ischemic heart disease (BMD) by using BM-MSCs. It is believed that with the deepening of the research, human beings are bound to utilize this new strategy of mesenchymal stem cell therapy to overcome a series of IHD therapies problem.